Hengrui Pharma And Braveheart Bio Report Durable 52-Week HRS/BHB-1893 Benefits In oHCM; Says Data Across Both Forms Of HCM And Preclinical Models Suggest Potential To Address Underlying Pathophysiology Of Disease, Findings Consistent With Reverse-remodeling And Diastolic Benefits; To Host Investor Event And Webcast Today At 4:35 p.m. ET
HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeksData support a
Braveheart's heart drug showed strong results over a full year of testing. Watch whether doctors and patients view this medicine as better than current options.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.